Alerta

REAGENTS AND METHODS FOR PREVENTING, TREATING OR LIMITING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS INFECTION

Resumen de: US20260263588A1

Polypeptides and nucleic acids encoding the polypeptides are provided that include severe acute respiratory syndrome Co-V-2 (SARS-CoV-2) spike polypeptide receptor-binding domain (RBD) polypeptides that include at least one non-naturally occurring N-linked glycosylation motif in any of the residues 369-372, 388-390, 405-407, 417-419, 437-441, 477-479, 487-489 and 501-503, which are capable of multimerization and thus presenting multiple copies of the RBD to enhance the immune response generated when the polypeptide is administered to a subject.

MULTI-OMIC PROFILING SIGNATURES FOR COVID-19

Resumen de: US20260265825A1

0000 A signature for identifying a subject at risk of developing a severe reaction to a SARS-CoV virus by detecting one or more of elevated serum cytokines, reduced monocyte subclasses, differentially expressed genes in monocyte subclasses, differentially expressed gene in CD8+ effector memory T cells, and elevated chromatin accessibility in intermediate monocytes are disclosed herein. Also disclosed are methods for obtaining the signature, methods of identifying a subject at risk of developing a severe reaction to a SARS-CoV virus, and methods of treating COVID-19.

METHODS OF TREATING FIBROSIS

Resumen de: AU2025233025A1

Described herein are methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

SARS-COV2 ANTIBODIES AND METHODS OF USE THEREOF

Resumen de: US20260265350A1

The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS

Resumen de: US20260263430A1

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

T CELL BROAD BETACORONAVIRUS VACCINE

Resumen de: WO2026185415A1

The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the prophylactic or therapeutic treatment of an infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2.

SYSTEM, APPARATUS, AND METHOD FOR VIRAL MONITORING IN EFFLUENT

Resumen de: US20260266815A1

A system for viral monitoring in effluent includes at least one graphene-based field-effect transistor and circuitry, wherein the circuitry is configured to repeatedly monitor and determine presence of SARS-CoV-2 (COVID virus) in the effluent. The circuitry is configured to apply a gate voltage and measure a conductance across each of the at least one graphene-based field-effect transistor, compare the measured conductance across each of the at least one graphene-based field-effect transistor to a threshold conductance, and determine whether levels of the COVID virus exceed a predetermined threshold in the effluent. If levels of the COVID virus exceed the predetermined threshold in the effluent, the circuitry is configured to remove at least a portion of the bound COVID virus from the proteins of the at least one graphene-based field-effect transistor.

METHODS OF TREATING FIBROSIS

Resumen de: US20260263460A1

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

PROTEIN AND VACCINE AGAINST INFECTION BY SARS-COV-2 OMICRON VARIANT STRAIN AND SUBTYPE THEREOF

Resumen de: US20260263587A1

The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-COV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-COV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-COV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-COV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-COV-2 Omicron mutant strain and subtype viruses thereof.

METHOD FOR TREATING COVID-19 INFECTION IN A HUMAN SUBJECT

Resumen de: US20260263510A1

0000 A method of treating a COVID-19 infection including administering to a subject in need thereof an effective amount of a composition, where the composition includes silica nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), chitosan, cisplatin, ribavirin, and an angiotensin-converting enzyme 2 (ACE-2). The SPIONs and ACE-2 are dispersed on an outer surface of the silica nanoparticles. The chitosan at least partially wraps around the outer surface of the silica nanoparticles. The cisplatin and ribavirin are in pores of the silica nanoparticles. The particles of the composition are monodisperse, and spherical, and have an average diameter of 70-100 nanometers (nm).

PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM

Resumen de: US20260263473A1

In alternative embodiments, provided are pharmaceutical compositions and therapeutic combinations of drugs, including products of manufacture and kits, for treating, preventing or ameliorating (for example, decreasing the symptoms of, or decreasing the mortality of) a viral infection, for example, a coronavirus infection such as a COVID-19 or variant thereof, and methods for making and using same. In alternative embodiments, provided are products of manufacture and kits for delivering pharmaceutical compositions and therapeutic combinations of drugs as provided herein, for example provided are transdermal delivery devices such as patches that can have multiple compartments for delivering transdermally different drugs at the same time.

METHOD FOR DETERMINING THE LEVEL OF RISK OF SEVERE COVID-19 DISEASE IN A PATIENT

Resumen de: WO2025080149A1

A method for assaying the presence of two genetic polymorphisms whose occurrence significantly modifies the course of COVID-19 disease is disclosed. The genetic polymorphisms, namely rs143334143 locus and at the rs74956615. This method represents a new tool in the public health protection against COVID-19 disease.

COMPOSITIONS AND METHODS FOR TREATMENT OF SUBJECTS SUFFERING FROM A SARS-COV-2 INFECTION

Resumen de: US20260256871A1

0000 The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.

COVID-19 AND RESPIRATORY DISEASE VIRUS INFECTION MODELS USING LUNG ORGANOIDS

Resumen de: US20260259197A1

The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.

RECOMBINANT ADENOVIRUS COMPRISING SARS-COV-2-DERIVED RECEPTOR-BINDING DOMAIN AND ANTIBODY FC REGION, AND USE THEREOF

Resumen de: WO2026182475A1

The present invention relates to a recombinant adenovirus comprising a SARS-CoV-2-derived receptor-binding domain and an antibody Fc region, and a use thereof, and provides: a polynucleotide comprising a SARS-CoV-2 spike-derived receptor-binding domain and an antibody Fc region; a recombinant adenovirus comprising the polynucleotide; and a vaccine composition for preventing SARS-COV-2 infection, comprising the recombinant adenovirus as an active ingredient.

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Resumen de: US20260256905A1

0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

ASSAYS FOR THE EVALUATION OF SEASONAL COVID-INFLUENZA COMBINATION VACCINES

Resumen de: US20260259196A1

Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) from a subject that has been administered a an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus contains antibodies that inhibit influenza virus hemagglutinin (HA) glycoprotein hemagglutination activity, antibodies that neutralize SARS-COV-2 virus, antibodies that bind SARS-COV-2 spike protein, and/or antibodies that neutralize seasonal influenza virus. The methods include assaying a biological sample, where the biological sample is from a subject that has been administered an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus, and is not significantly affected by interference of analyte detection between the methods.

USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION

Resumen de: EP4799624A2

Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications associated with RNA viral infections. The methods, for example, can include administering pharmaceutical compositions comprising Pipendoxifene or analogues thereof (e.g., a compound of Formula (I), Formula (II), or Formula (III)) to a patient in need. One or more additional therapeutic agents can also be administered to the patient in the disclosed methods.

COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19

Resumen de: WO2025090605A1

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Nouveaux composés à base d’acides aminés modifiés comme inhibiteurs de la réplication du SARS-CoV-2, leurs formulations et applications

Resumen de: MA70856A1

Cette invention est relative à de nouveaux composés à base de lacide éthacrynique couplé avec des acides aminés modifiés comme lillustre la formule (I). Ces composés sont conçus pour le traitement du SARS-CoV-2, des pathologies liées à la COVID-19, ainsi que des maladies associées aux -coronavirus. Cette invention porte également sur leur application in vitro pour étudier l'inhibition de la réplication du SARS CoV2. De plus, cette invention inclut des compositions pharmaceutiques comprenant, comme principe actif, au moins un composé de la formule (I).

Treatment of pathological fatigue with oxaloacetate

Resumen de: NZ801710A

The present disclosure relates to methods of treatment and compositions for treatment of Pathological Fatigue caused by injury or disease in the body. Pathological fatigue refers to physical and mental fatigue that is caused by viral infection, bacterial infection, trauma, disease, or genetic alteration that results in fatigue that is not improved by bed rest and may be worsened by physical or mental activity. Such pathologic fatigue occurs in myalgic encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) and other disorders such as such as post-COVID-19 fatigue, post-viral fatigue, fibromyalgia (FM), cancer, Parkinson’s Disease, other diseases and trauma as well as of combinations thereof. Related treatment methods and pharmaceutical compositions are also disclosed.

Methods and modified nucleosides for treating coronavirus infections

Resumen de: NZ802021A

Provided are methods for treating coronavirus infections by administering modified nucleosides, ester and amino acid ester prodrugs of nucleoside, their pharmaceutically acceptable salts, and drug combination thereof, of Formula (I). The compounds, combination, and methods provided are particularly useful for preventing, mitigating, or treating coronavirus infections or cytopathic effects resulting from the replication or reproduction of coronaviruses and their variants, including SARS-CoV-2.

FUSION PROTEIN OF ULTRA-STABLE INTRACELLULAR ANTIBODY TARGETING PDIA3 AND USE THEREOF

Resumen de: WO2026175420A1

Provided are a fusion protein of an ultra-stable intracellular antibody targeting PDIA3 and the use thereof. The fusion protein comprises an antigen-binding peptide targeting PDIA3 and an intracellular stabilizing peptide. The antigen-binding peptide comprises a heavy chain variable region and a light chain variable region. By means of optimally designed intracellular stabilizing peptide and signal peptide sequences, the antibody can stably exist in cells and specifically localize to the endoplasmic reticulum. The fusion protein can effectively target and bind to the PDIA3 protein, significantly inhibit the expression levels of S proteins from human coronaviruses and capsid proteins from various non-enveloped viruses in cells, and regulate endoplasmic reticulum stress via protein-protein interactions on the ER of host cells, thereby promoting the degradation of the viral proteins and further effectively reducing the infectivity of the viruses.

MULTI-PATCH VACCINES AND IMMUNOGENIC COMPOSITIONS, METHODS OF PRODUCTION AND USES THEREOF

Resumen de: US20260250326A1

0000 The present invention relates to a method for producing immunogenic compositions, such as vaccines, by identifying amino acid sequence of antigenic patches (Ag-Patches) from at least one proteome of a pathogen, derived from overlapping epitope clusters. In particular, the invention relates to the design of Multi-Patch Vaccines against viral, such as SARS-CoV-2, bacterial, fungi, parasite, pathogenic and non-pathogenic targets.

RECOMBINANT HPV16 E6E7 ADENOVIRUS, VACCINE THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF

Nº publicación: WO2026174523A1 27/08/2026

Solicitante:

WESTVAC BIOPHARMA CO LTD [CN]
\u6210\u90FD\u5A01\u65AF\u514B\u751F\u7269\u533B\u836F\u6709\u9650\u516C\u53F8

Resumen de: WO2026174523A1

The present invention relates to the field of cancer immunotherapy technology, and specifically, to a recombinant HPV16 E6E7 adenovirus, a vaccine thereof, a method for preparing same, and use thereof. The present invention provides a recombinant HPV16 E6E7 adenovirus, comprising an HPV16 E6E7 antigen sequence and SARS-CoV-2 virus HR1 and HR2 region sequences. The recombinant HPV16 E6E7 adenovirus vaccine prepared by using the adenovirus, when used either alone or in combination with other anti-tumor drugs, can significantly inhibit the growth of tumors in cervical cancer and head and neck squamous cell carcinoma, and induce a significant cellular immune response in mice.